<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From September 1982 to August 1997, 767 bone marrow or peripheral blood stem cell transplants have been performed at the Health Sciences Center in Oklahoma </plain></SENT>
<SENT sid="1" pm="."><plain>Five hundred and two (502) autologous transplants (AutoTX) preceded by high-dose myeloablative therapy were performed for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (BC, 36%), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL, 24%), <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, 10%), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 8%), <z:e sem="disease" ids="C0153594" disease_type="Neoplastic Process" abbrv="">testicular cancer</z:e> (TC, 4%), <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM, 2%) and other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (16%) </plain></SENT>
<SENT sid="2" pm="."><plain>Two hundred and sixty-five (265) allogeneic marrow transplants (AlloTX) (related, unrelated) were carried out in <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>, 30%), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (23%), <z:hpo ids='HP_0006721'>acute lymphoid leukemia</z:hpo> (ALL, 14%), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 9%), severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA, 8%), and other diseases (14%) </plain></SENT>
<SENT sid="3" pm="."><plain>Compared between 1980s to 1990s, 100-day mortality rates have decreased from 28% to 5% for AutoTX and from 40% to 25% for AlloTX </plain></SENT>
<SENT sid="4" pm="."><plain>In the AutoTX setting, major changes included the routine use of growth factors post-transplant and the switch from bone marrow to growth factor-mobilized peripheral blood as a source of stem cells over the last five years </plain></SENT>
<SENT sid="5" pm="."><plain>In the AlloTX setting, improvements in recognition and control of cytomegalovirus and Candida organisms, the selective use of growth factors and screened blood products, and better selection of unrelated donors using DNA-based techniques of HLA-matching have contributed to reduce early mortality from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and primary graft failure </plain></SENT>
<SENT sid="6" pm="."><plain>The five-year survival outcomes are comparable to those reported in registry data from the International Bone Marrow Transplant Registry (IBMTR) and the National Marrow Donor Program (NMDP) </plain></SENT>
</text></document>